Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

High-Intensity Interval Training × Thoracic × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Lymphoid 1 Gynecologic 1 Gastrointestinal 1 CNS 1 Breast 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 319 pembrolizumab 301 Pemetrexed 229 Cisplatin 196 Paclitaxel 139 durvalumab 131 Nivolumab 123 osimertinib 96 Docetaxel 93 atezolizumab 92 Specimen Handling 80 Drug Therapy 79 Radiotherapy 70 Magnetic Resonance Spectroscopy 70 Etoposide 64 Gemcitabine 59 Radiosurgery 57 Ipilimumab 47 Bevacizumab 47 tislelizumab 44 130-nm albumin-bound paclitaxel 44 cemiplimab 40 Blood Specimen Collection 35 Biopsy 30 Taxes 29 Standard of Care 29 Platinum 28 Immunotherapy 28 Immune Checkpoint Inhibitors 28 Cetuximab 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06026111 2026-01-21

ENHANCE

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡